San Luis Wealth Advisors LLC Invests $623,000 in Cencora, Inc. (NYSE:COR)

San Luis Wealth Advisors LLC purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,240 shares of the company's stock, valued at approximately $623,000.

Several other large investors also recently added to or reduced their stakes in the company. Whittier Trust Co. raised its stake in Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after purchasing an additional 44 shares during the period. WASHINGTON TRUST Co raised its stake in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the period. JFS Wealth Advisors LLC raised its stake in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. Cullen Frost Bankers Inc. raised its stake in Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after purchasing an additional 47 shares during the period. Finally, Permanent Capital Management LP raised its stake in Cencora by 4.0% during the 1st quarter. Permanent Capital Management LP now owns 1,238 shares of the company's stock valued at $344,000 after purchasing an additional 48 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares in the company, valued at approximately $85,680,732.63. This trade represents a 4.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,253 shares of company stock worth $10,582,297 over the last ninety days. Company insiders own 10.80% of the company's stock.

Cencora Stock Performance

COR stock traded up $0.08 during mid-day trading on Friday, reaching $295.12. 966,888 shares of the stock traded hands, compared to its average volume of 1,528,880. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35. The business has a 50-day moving average of $287.24 and a two-hundred day moving average of $261.74. The firm has a market capitalization of $57.20 billion, a PE ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same period in the prior year, the company earned $3.80 earnings per share. The business's quarterly revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on COR shares. Robert W. Baird upped their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Citigroup upped their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.